Synthesis of para- and meta-imino- or -amino-methyl pyridyl-appended p-tert-butyl-calix[4]arene or p-tert-butyl-thiacalix[4]arene in 1,3-alternate conformation

Mohamed Noamane, Sylvie Ferlay, Rym Abidi, Nathalie Kyritsakas, Mir Wais Hosseini

► To cite this version:

Mohamed Noamane, Sylvie Ferlay, Rym Abidi, Nathalie Kyritsakas, Mir Wais Hosseini. Synthesis of para- and meta-imino- or -amino-methyl pyridyl-appended p-tert-butyl-calix[4]arene or p-tert-butyl-thiacalix[4]arene in 1,3-alternate conformation. *New Journal of Chemistry*, 2017, 41 (14), pp.6334-6339. 10.1039/C7NJ01389B . hal-02301792

HAL Id: hal-02301792

<https://hal.science/hal-02301792>

Submitted on 25 Nov 2020

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Synthesis of *para*- and *meta*-imino- or -amino-methyl pyridyl appended *p*-*tert*-butyl-calix[4]arene or *p*-*tert*-butyl-thiacalix[4]arene in 1,3-Alternate conformation

Received 00th January 20xx,
Accepted 00th January 20xx

DOI: 10.1039/x0xx00000x

www.rsc.org/

M. H. Noamane,^{a,b} S. Ferlay,^{a,*} R. Abidi,^b N. Kyrtsakas,^a M. W. Hosseini^{a,*}

The multistep synthesis of eight new ligands based on either calix[4]arene or thiocalix[4]arene backbone blocked in 1,3-Alternate conformation was achieved. Both types of backbones were functionalized with pyridyl coordinating units using either imino or amino junctions. The introduction of the pyridyl units was achieved using either the position 3 (*meta*) or 4 (*para*) of the aromatic moiety. Four out of the eight ligands have been structurally investigated in the solid state by X-ray diffraction methods on single crystals.

Dedicated to Prof. Bernard MEUNIER at the occasion of his 70th birthday.

Introduction

Calix[4]arene (CA, **1**, Figure 1)¹ and its analogue thiocalix[4]arene (TCA, **2**, Figure 1)², for which the four methylene groups connecting the phenolic moieties are replaced by S atoms, are interesting backbones interest for the design of receptors and/or ligands. Dealing with thiocalix[4]arene, the thioether junction may be oxidized leading to sulfinyl (SO)³ or sulfonyl (SO₂)⁴ groups. Not only these two scaffolds may be readily modified at both upper and lower rims, but in addition, these two tetraphenolic macrocycles adopt, for steric reasons, different limit conformations called cone, partial cone, 1,2-Alternate and 1,3-Alternate. Thus, the combination of these two features opens the way to the design of a large variety of abiotic compounds.

Among the four possible conformations mentioned above, the 1,3-Alternate conformation, displaying a S₄ symmetry, is of interest since it allows to position, in an alternate fashion, up to four interaction sites above and below the macrocyclic backbone. In particular, introduction of coordinating units leads to the formation of new discrete complexes⁵ or extended coordination networks.⁶

Both CA and TCA backbones have been decorated, both at the upper and/or the lower rims, with monodentate N donor ligands such as cyano⁷ or pyrazolyl⁸ units. Examples of

thiocalix[4]arene derivatives in different conformations (cone, partial cone, and 1,3-Alternate) bearing four pyridyl units at the lower rim using ester junctions between the macrocyclic moiety and pyridyl group have been described.⁹ Examples of tetrasubstituted calix[4]arene derivatives in cone conformation bearing coordinating sites at the upper and lower rims and their propensity to bind transition metals in solution have been reported.¹⁰ The formation of coordination networks resulting from combinations of metal actions such as Hg²⁺, Cd²⁺, Fe²⁺, Co²⁺ and Ag⁺ with thiocalix[4]arene derivatives blocked in 1,3-Alternate conformation and bearing pyridyl units at the lower rim has been described.¹¹ Thiocalix[4]arene derivatives in different conformations bearing two pyridyl moieties at their lower rim have been prepared and their binding ability in solution towards silver cation have been described.¹²

Here, we report on the design and detailed synthesis of eight new ligands based on either calix[4]arene or thiocalix[4]arene backbones in 1,3-Alternate conformation bearing at their upper rim imino- or amino-methyl-pyridyl coordinating units (compounds **3–10**, figure 1). The *para*- and *meta*-imino- or -amino-methyl pyridyl derivatives have been used for the formation of new complexes or coordination polymers.¹³

^a Molecular Tectonics Laboratory, Université de Strasbourg, CNRS, CMC UMR 7140, F-67000 Strasbourg, France

^b Université de Carthage, Laboratoire d'Application de la Chimie aux Ressources et Substances Naturelles et à l'Environnement (LACReSNE), unité des interactions moléculaires spécifiques, Faculté des Sciences de Bizerte, 7021 Bizerte, Tunisia
See DOI: 10.1039/x0xx00000x

Figure 1: Calix[4]arene (CA, 1) and thiacalix[4]arene (TCA, 2) in 1,3-Alternate conformation, used as platform for the design of ligands bearing four imino or amino-*meta* and *para*-pyridyl units 3-10.

Results and discussion

Design of ligands 3-10

The design of ligands 3-10 (Figure 1) is based on the *p*-*tert*butylcalix[4]arene (1) or *p*-*tert*butyltetra-thiacalix[4]arene (2) backbones in 1,3-Alternate conformation. This type of platform, displaying a S₄ symmetry, offers the possibility to introduce up to four interacting sites in an alternate fashion below and above the mean plane of the macrocyclic moiety. Both types of backbones were functionalized at the lower rim with pyridyl coordinating units (3, 5, 7 and 9 based on 1 and (4, 6, 8, and 10 based on 2). The introduction of the pyridyl units was achieved using either the position 3 (*meta*, ligands 3, 4, 7 and 8) or 4 (*para*, ligands 5, 6, 9 and 10) of the aromatic moiety. In all cases, a propyl fragment was used to connect the pyridyl units to the calix backbone using either an iminomethyl (N=CH, compounds 3-6) or an aminomethyl (N-CH₂, compounds 7-10) junctions. Within each family of compounds (imino or amino derivatives), ligands 3 and 5, 4 and 6, 7 and 9 and 8 and 10 are positional isomers.

Compounds 3-10 were prepared by multistep synthesis following a strategy reported for the synthesis of analogues bearing pyridyl units connected using the position 2 (*ortho*).¹⁴ The key intermediates for which the 1,3-Alternate conformation of the calix moiety is imposed, were phthalimide derivatives 11¹⁵ and 13¹⁶ (Figure 2).

The phthalimido derivatives 11¹⁴ and 13¹⁶ were prepared in 55 and 68 % yields respectively upon condensation in the presence of Cs₂CO₃ as base of *N*-(3-bromopropyl)phthalimide with calix[4]arene 1 or thiacalix[4]arene 2. Compounds 11 and 13 were converted into the corresponding amino derivatives 12 and 14 by treatment with hydrazine.^{17,16b}

Figure 2: Precursors 11-16 used for the synthesis of ligands 3-10.

The condensation, at room temperature, of the amino derivatives 12 or 14 with 3-Pyridinecarboxaldehyde 15 or 4-Pyridinecarboxaldehyde 16 in a EtOH/DMF (1/1) mixture, afforded the final ligands 3-6 with yields varying between 64% and 81% (Table 1).

Table 1: Yields for the condensation of the amino derivatives 12 and 14 with 3-Pyridinecarboxaldehyde 15 or 4-Pyridinecarboxaldehyde 16 leading to the formation of iminomethylpyridyl ligands 3-6 and for the formation of aminomethylpyridyl 7-10 obtained upon reduction of the imino groups.

Compound	3	4	5	6
Yield (%)	74	71	64	81
Compound	7	8	9	10
Yield (%)	76	94	93	91

The imino derivatives 3-5 were converted into the amino compounds 7-9 in 76 - 94% yield (Table 1) by reduction using NaBH₄/MeOH as reducing mixture. The conversion of 6 into 10 was achieved a yield of 91 % yield using LiAlH₄/THF.

All ligands 3-10 were fully characterized in solution by ¹H- and ¹³C-NMR spectroscopy and mass spectrometry. As expected, the ¹H-NMR study revealed that the imino N=CH group signals for 3-6 are downfield shifted (in the 8.04 - 8.11 range) with respect to signals corresponding to the amino HN-CH₂ unit in 7-10 (in the 3.59 - 3.76 range).

Solid-state description of ligands 4, 5, 6 and 8

Among the 8 new ligands, four, compounds 4, 5, 6 and 8, have been characterized in the solid state by X-ray diffraction on single crystals (see Crystallographic table 3). Crystals of compounds 4, 6 and 8 were obtained upon CH₃CN vapour diffusion into a CHCl₃ solutions of the ligand. Crystals of 5 were obtained upon slow evaporation of solution of CHCl₃ containing 5 (see experimental section).

In agreement with NMR studies in solution, all four compounds 4, 5, 6 and 8 are, as expected, in 1,3-Alternate conformation in the crystalline phase (Figure 3). All four

ligands crystallise in the $P2_1/n$ space groups (monoclinic system). Whereas crystals of compounds **5** and **6** contain CHCl_3 solvent molecules with no specific interactions with the ligand, for ligands **4** and **8**, solvent molecules could not be refined and squeeze command was applied to solve the structure.¹⁸

For compounds **4**, **5**, **6** and **8**, the metrics for the macrocyclic part are close to those observed for the parent CA and TCA and will not be detailed here. Relevant bond distances and angles are gathered in table 2. In all four cases, one of the four *tert*-butyl groups I was found to be disordered.

For the imino-derivative **4**, **5** and **6**, the C=N distances are in the 1.169(14)-1.266(8) Å range (see table 2) with the CNC angles ranging from 109.6(10)° to 118.8(9)°. For the amino derivative **8**, the HC-NH distances are in the 1.388(10)-1.488(18) range with CNC angles ranging from 113.0(8)° to 114.6(6)° confirming thus the presence of sp^3 nitrogen atoms.

Table 2: Relevant angles and distances for compounds **4**, **5**, **6**, and **8**.

	4	5	6	8
$d_{\text{CAr-S}}$ (Å)	1.755(8) - 1.782(8)	-	1.763(4)- 1.780(4)	1.760(4)- 1.774(5)
$d_{\text{CAr-C}}$ (Å)	-	1.513(5)- 1.522(4)	-	-
$d_{\text{O-CAr}}$ (Å)	1.346(13)- 1.453(9)	1.363(9)- 1.422(4)	1.355(5)- 1.436(5)-	1.363(5)- 1.446(12)
C=N	1.169(14)	1.178(5)	1.200(7)	
(imino)	1.240(11)	1.210(5)	1.223(6)	
	1.244(12)	1.253(5)	1.245(7)	
	1.265(13)	1.258(4)	1.266(8)	
C-NH				1.388(10)
(amino)	-	-	-	1.442(9)
				1.459(9)
				1.488(18)
CNC	109.6(10)	113.1(5)	116.5(6)	113.0(8)
(imino or	116.8(9)	116.8(4)	117.0(5)	113.5(9)
amino)	117.6(9)	117.9(5)	118.3(6)	114.1(6)
	118.8(9)	118.0(3)	118.7(5)	114.6(6)

Figure 3: Solid-state structures of **4** (top left), **5** (top right), **6** (bottom left) and **8** (bottom right) showing the 1,3-Alternate conformation of backbones. H atoms, except for compound **8**, and solvent molecules in the case of compound **5** and **6** are not presented for clarity. For bond distances and angles see text.

Conclusions

Eight new ligands **3-10** based on either calix[4]arene or thiacalix[4]arene backbones blocked in 1,3-Alternate conformation were designed and synthesized using multistep strategies. The two backbones were equipped with four pyridyl derivatives located, in an alternate fashion, above and below the mean plane of the macrocyclic units. Ligands **3-10**, while all based on the same propyl spacer, differ by the nature of the junction (imino or amino groups) and by the position of the junction on the pyridyl units (*meta* or *para*). All ligands have been fully characterized in solution and, for **4**, **5**, **6** and **8**, by X-ray diffraction on single crystals in the solid state.

In solution, the coordination propensity of ligands **3-10** towards metal cations such as Ni^{2+} , Co^{2+} , Zn^{2+} , Mn^{2+} , Cu^{2+} and Ag^+ is under investigation. Furthermore, combinations of compounds **3-10** used as tectons with metal cations to generate extended coordination networks in the crystalline phase under self-assembly processes is currently under study.

Experimental

Materials and methods

^1H -NMR and ^{13}C -NMR spectra were recorded at room temperature on a Bruker (300, 400 or 500 MHz) NMR spectrometer.

Mass spectra (ESI) were obtained on a MicroTOF-Q (BRUKER) equipped with an electrospray source.

Microanalyses were performed by the Service de Microanalyses de la Fédération de Recherche Chimie, Université de Strasbourg, Strasbourg, France.

Melting points were measured in capillary on a Stuart Scientific Melting Point SMP-1 apparatus.

Single-Crystal Studies

Data were collected at 173(2)K on a Bruker Apex-II-CCD Diffractometer equipped with an Oxford Cryosystem liquid N₂ device, using graphite-monochromated Mo-K α ($\lambda = 0.71073$ Å) radiation. For all the structures, diffraction data were corrected for absorption. Structures were solved using SHELXS-97 and refined by full matrix least-squares on F² using SHELXL-97. The hydrogen atoms were introduced at calculated positions and not refined (riding model).¹⁹ They can be obtained free of charge from the Cambridge Crystallographic Data Centre via www.ccdc.cam.ac.uk/datarequest/cif. CCDC: 1545778-1545781.

Synthetic procedures

General: All reagents were purchased from commercial sources and used without further purification. *p*-tert-butylcalix[4]arene **1** is commercially available and *p*-tert-butylthiacalix[4]arene **2** was prepared according to the literature procedures.² The synthesis of compounds **11–14** has been reported.¹⁴

All reactions were performed under a N₂ atmosphere.

5,11,17,23-Tetra-tert-butyl-25,26,27,28-tetrakis-(3-pyridylideniminopropoxy)calix[4]arene (3)

3-Pyridinecarboxaldehyde **15** (440 μ L, 4.55 mmol) and compound **12** (0.5 g, 0.56 mmol) were dissolved in 40 mL of a EtOH/DMF (1/1) mixture and stirred at room temperature during 2 days. 100 mL of CH₃CN was added to the mixture and the white precipitate thus formed was filtrated and washed several times with petroleum ether (60 mL). Filtrates were combined and placed in the refrigerator over a period of one week leading to further precipitation. Precipitates were combined affording the desired compound **3** in 1,3-Alternate conformation as a white solid (0.52 g, 74 %). mp = 122 °C. ¹H-NMR (300 MHz, CDCl₃, 25 °C): δ (ppm) = 1.23 (36H, s, *t*-Bu), 1.38 (8H, m, CH₂-CH₂-CH₂), 3.38 (8H, t, N-CH₂), 3.48 (8H, t, Ar-O-CH₂), 3.82 (8H, s, Ar-CH₂-Ar), 6.96 (8H, s, Ar-H), 7.30 (4H, m, Py-H), 8.00 (4H, t, Py-H), 8.11 (4H, s, Py-CH=N), 8.60 (4H, d, Py-H), 8.79 (4H, d, Py-H). ¹³C-NMR (125 MHz, CDCl₃, 25 °C): δ (ppm) = 30.3, 31.7, 34, 39.1, 58.8, 68.1, 123.6, 125.6, 131.8, 133.0, 134.4, 143.8, 150.0, 151.2, 154.6, 157.2. MS (ESI), *m/z*: 1233.76 {[M]⁺, calculated 1233.67}. Anal. Calcd. for C₈₀H₉₆N₈O₄•H₂O: C, 76.77%; H, 7.89%; N, 8.95%; Found: C, 76.41 %; H, 7.98%; N, 8.83%. UV-vis (CHCl₃/MeOH (1/1)): λ_{max} (nm) / ϵ (mol⁻¹Lcm⁻¹) = 239(62668). IR (cm⁻¹): $\nu_{\text{C=N}}$: 1649.

5,11,17,23-Tetra-tert-butyl-25,26,27,28-tetrakis-(3-pyridylideniminopropoxy)thiacalix[4]arene (4)

3-Pyridinecarboxaldehyde **15** (560 μ L, 5.84 mmol) and compound **14** (0.7 g, 0.73 mmol) were dissolved in 40 mL of a EtOH/DMF (1/1) mixture and stirred at room temperature during 2 days. 100 mL of CH₃CN was added to the mixture and the white precipitate thus formed was filtrated and washed several times with petroleum ether (100 mL). Washes were combined and placed in the refrigerator over a period of one

week leading to further precipitation which was filtered. Precipitates were combined affording the desired compound **4** in 1,3-Alternate conformation as a white solid (0.65 g, 70.6 %). mp = 188 °C. ¹H-NMR (300 MHz, CDCl₃, 25 °C): δ (ppm) = 1.21 (36H, s, *t*-Bu), 1.39 (8H, m, CH₂-CH₂-CH₂), 3.39 (8H, t, N-CH₂), 3.97 (8H, t, Ar-O-CH₂), 7.29 (4H, m, Py-H), 7.31 (8H, s, Ar-H), 8.01 (4H, m, Py-H), 8.12 (4H, s, Py-CH=N), 8.60 (4H, d, Py-H), 8.79 (4H, d, Py-H). ¹³C-NMR (75 MHz, CDCl₃, 25 °C): δ (ppm) = 30.0, 31.3, 34.3, 58.8, 66.6, 123.6, 127.5, 128, 131.8, 134.4, 145.7, 150.0, 151.3, 156.8, 157.4. MS (ESI), *m/z*: 1305.59 {[M]⁺, calculated 1305.82}. Anal. Calcd. for C₇₆H₈₈N₈O₄S₄•C₂H₅OH•H₂O: C, 68.39%; H, 7.06%; N, 8.18%; Found: C, 68.47 %; H, 6.68%; N, 8.20%. UV-vis (CHCl₃/MeOH (1/1)): λ_{max} (nm) / ϵ (mol⁻¹Lcm⁻¹) = 239(58044). IR (cm⁻¹): $\nu_{\text{C=N}}$: 1648.

5,11,17,23-Tetra-tert-butyl-25,26,27,28-tetrakis-(4-pyridylideniminopropoxy)calix[4]arene (5)

4-Pyridinecarboxaldehyde **16** (440 μ L, 4.55 mmol) and compound **12** (0.5 g, 0.56 mmol) were dissolved in 40 mL of a EtOH/DMF (1/1) mixture and stirred at room temperature during 2 days. 100 mL of CH₃CN was added to the mixture and the white precipitate thus formed was filtrated and washed several times with petroleum ether (60 mL). Filtrates were combined and placed in the refrigerator over a period of one week leading to further precipitation. Precipitates were combined affording the desired compound **5** in 1,3-Alternate conformation as a white solid (0.45 g, 64 %). mp = 166 °C. ¹H-NMR (300 MHz, CDCl₃, 25 °C): δ (ppm) = 1.23 (36H, s, *t*-Bu), 1.36 (8H, m, CH₂-CH₂-CH₂), 3.38 (8H, t, N-CH₂), 3.47 (8H, t, Ar-O-CH₂), 3.82 (8H, s, Ar-CH₂-Ar), 6.96 (8H, s, Ar-H), 7.50 (8H, d, Py-H), 8.04 (4H, s, Py-CH=N), 8.65 (8H, d, Py-H). ¹³C-NMR (75 MHz, CDCl₃, 25 °C): δ (ppm) = 30.1, 31.7, 34, 39.2, 58.8, 68.0, 121.8, 125.5, 133.0, 143.0, 143.9, 150.4, 154.6, 158.2. MS (ESI), *m/z*: 1234.76 {[M+H]⁺, calculated 1234.67}. Anal. Calcd. for C₈₀H₉₆N₈O₄•H₂O: C, 76.77%; H, 7.89%; N, 8.95%; Found: C, 76.41%; H, 7.98%; N, 8.83%. UV-vis (CHCl₃/MeOH (1/1)): λ_{max} (nm) / ϵ (mol⁻¹Lcm⁻¹) = 238(38180). IR (cm⁻¹): $\nu_{\text{C=N}}$: 1649.

5,11,17,23-Tetra-tert-butyl-25,26,27,28-tetrakis-(4-pyridylideniminopropoxy)thiacalix[4]arene (6)

4-Pyridinecarboxaldehyde (560 μ L, 5.84 mmol) **16** and compound **14** (0.7 g, 0.73 mmol) were dissolved in 40 mL of a EtOH/DMF (1/1) mixture and stirred at room temperature during 2 days. 100 mL of CH₃CN was added to the mixture and the white precipitate thus formed was filtrated and washed several times with petroleum ether (100 mL). Filtrates were combined and placed in the refrigerator over a period of one week leading to further precipitation. Precipitates were combined affording the desired compound **6** in 1,3-Alternate conformation as a white solid (0.78 g, 81 %). mp = 244 °C. ¹H-NMR (300 MHz, CDCl₃, 25 °C): δ (ppm) = 1.21 (36H, s, *t*-Bu), 1.38 (8H, m, CH₂-CH₂-CH₂), 3.39 (8H, t, N-CH₂), 3.97 (8H, t, Ar-O-CH₂), 7.31 (8H, s, Ar-H), 7.50 (8H, d, Py-H), 8.06 (4H, s, Py-CH=N), 8.64 (8H, d, Py-H). ¹³C-NMR (100 MHz, CDCl₃, 25 °C): δ (ppm) = 29.8, 31.3, 34.3, 58.7, 66.5, 121.8, 127.4, 128.0, 143.0, 145.7, 150.4, 156.7, 158.4. MS (ESI), *m/z*: 1306.59

{[M+H]⁺, calculated 1306.82}. Anal. Calcd. for C₇₆H₈₈N₈O₄S₄•C₂H₅OH•H₂O: C, 68.54%; H, 6.86%; N, 8.20%; Found: C, 68.76%; H, 6.71%; N, 8.11%. UV-vis (CHCl₃/MeOH (1/1)): λ_{max} (nm) / ε (mol⁻¹Lcm⁻¹) = 238(57909). IR (cm⁻¹): ν_{C=N}: 1647.

5,11,17,23-Tetra-tert-butyl-25,26,27,28-tetrakis -[(3-pyridinylmethylamino)propoxy]calix[4]arene (7)

NaBH₄ (0.31g, 8.1 mmol) and compound **3** (0.5 g, 0.4 mmol) were dissolved in 30 mL of MeOH and refluxed during 2 days. 50 mL of water was added carefully and the product was extracted three times with CHCl₃ (3x50 mL). The organic phase was evaporated to dryness affording the desired compound **7** in 1,3-Alternate conformation as a white solid (0.38 g, 76 %). mp = 138 °C. ¹H-NMR (500 MHz, CDCl₃, 25 °C): δ(ppm) = 1.23 (8H, m, CH₂-CH₂-CH₂), 1.23 (36H, s, t-Bu), 2.24 (8H, t, CH₂-N), 3.36 (8H, t, Ar-O-CH₂), 3.63 (8H, s, Ar-CH₂-Ar), 3.74 (8H, s, NH-CH₂-Py), 6.92 (8H, s, Ar-H), 7.18 (4H, t, Py-H), 7.56 (4H, d, Py-H), 8.44 (4H, d, Py-H), 8.47 (4H, d, Py-H). ¹³C-NMR (125 MHz, CDCl₃, 25 °C): δ(ppm) = 30.1, 31.7, 33.9, 39.0, 46.4, 51.4, 68.5, 123.3, 125.7, 133.0, 135.6, 135.9, 143.6, 148.4, 149.6, 154.5. MS (ESI), m/z: 1241.82 {[M]⁺, calculated 1241.73}. Anal. Calcd. for C₈₀H₁₀₄N₈O₄•H₂O: C, 76.27%; H, 8.48%; N, 8.89%; Found: C, 76.53%; H, 8.42%; N, 8.52%. UV-vis (CHCl₃/MeOH (1/1)): λ_{max} (nm) / ε (mol⁻¹Lcm⁻¹) = 237(51820). IR (cm⁻¹): ν_{NH}: 3293.

5,11,17,23-Tetra-tert-butyl-25,26,27,28-tetrakis -[(3-pyridinylmethylamino)propoxy]thiacalix[4]arene (8)

NaBH₄ (0.18g, 4.66 mmol) and compound **4** (0.3 g, 0.23 mmol) were dissolved in 30 mL of MeOH and refluxed during 2 days. 50 mL of water was added carefully and the product was extracted three times with CHCl₃ (3x50 mL). The organic phase was evaporated to dryness affording the desired compound **8** in 1,3-Alternate conformation as a white solid (0.28 g, 94 %). mp = 192 °C. ¹H-NMR (300 MHz, CDCl₃, 25 °C): δ(ppm) = 1.15 (8H, m, CH₂-CH₂-CH₂), 1.22 (36H, s, t-Bu), 2.37 (8H, t, CH₂-N), 3.59 (8H, s, NH-CH₂-Py), 3.86 (8H, t, NH-CH₂-Py), 7.18 (4H, m, Py-H), 7.27 (8H, s, Ar-H), 7.53 (4H, t, Py-H), 8.43 (4H, d, Py-H), 8.45 (4H, d, Py-H). ¹³C-NMR (125 MHz, CDCl₃, 25 °C): δ(ppm) = 29.4, 31.3, 34.3, 46.2, 51.3, 66.6, 123.3, 127.4, 127.9, 135.6, 135.9, 145.6, 148.4, 149.6, 156.7. MS (ESI), m/z: 1313.65 {[M]⁺, calculated 1313.89}. Anal. Calcd. for C₇₆H₉₆N₈O₄S₄•H₂O: C, 68.53%; H, 7.42%; N, 8.41%; Found: C, 68.25%; H, 7.32%; N, 8.18%. UV-vis (CHCl₃/MeOH (1/1)): λ_{max} (nm) / ε (mol⁻¹Lcm⁻¹) = 265(49900). IR (cm⁻¹): ν_{NH}: 3300.

5,11,17,23-Tetra-tert-butyl-25,26,27,28-tetrakis -[(4-pyridinylmethylamino)propoxy]calix[4]arene (9)

NaBH₄ (0.31g, 8.1 mmol) and compound **7** (0.5 g, 0.4 mmol) were dissolved in 40 mL of MeOH and refluxed during 2 days. 50 mL of water was added carefully and the product was extracted three times with CHCl₃ (3x50 mL). The organic phase was evaporated to dryness and the white precipitate is dried under vacuum at 70°C during 24hrs. The desired compound, **9**, in 1,3-Alternate conformation, is obtained as a white solid (0.47 g, 93 %). mp = 142 °C. ¹H-NMR (500 MHz, CDCl₃, 25 °C): δ(ppm) = 1.24 (36H, s, t-Bu), 1.24 (8H, m, CH₂-CH₂-CH₂), 2.40 (8H, t, CH₂-N), 3.39 (8H, t, Ar-O-CH₂), 3.65 (8H, s, Ar-CH₂-Ar),

3.76 (8H, s, NH-CH₂-Py), 6.93 (8H, s, Ar-H), 7.18 (8H, d, Py-H), 8.48 (8H, d, Py-H). ¹³C-NMR (125 MHz, CD₂Cl₂, 25 °C): δ(ppm) = 30.1, 31.7, 33.9, 39, 46.5, 52.8, 68.5, 122.8, 125.7, 133.1, 143.7, 149.7, 154.6. MS (ESI), m/z: 1241.82 {[M]⁺, calculated 1241.73}. Anal. Calcd. for C₈₀H₁₀₄N₈O₄: C, 77.38%; H, 8.44%; N, 9.02%; Found: C, 77.26%; H, 8.57%; N, 8.57%. UV-vis (CHCl₃/MeOH (1/1)): λ_{max} (nm) / ε (mol⁻¹Lcm⁻¹) = 237(24932). IR (cm⁻¹): ν_{NH}: 3258.

5,11,17,23-Tetra-tert-butyl-25,26,27,28-tetrakis -[(4-pyridinylmethylamino)propoxy]thiacalix[4]arene (10)

Compound **6** (0.2 g, 0.15 mmol) was dissolved in 30 mL of THF and stirred at 0°C. To this mixture, LiAlH₄ (0.057g, 1.5 mmol) was slowly added and the mixture was stirred at room temperature overnight. 30 mL of distilled water was added slowly and the mixture was further stirred at room temperature during two hours. The white precipitate thus formed was filtrated and dried under vacuum at 70 °C during 24 h. The desired compound **10**, in 1,3-Alternate conformation, was obtained as a white solid (0.18 g, 91 %). mp = 264 °C. ¹H-NMR (300 MHz, CD₂Cl₂, 25 °C): δ(ppm) = 1.16 (8H, m, CH₂-CH₂-CH₂), 1.26 (36H, s, t-Bu), 2.24 (8H, t, CH₂-N), 3.63 (8H, s, NH-CH₂-Py), 3.89 (8H, t, Ar-O-CH₂), 7.19 (8H, d, Py-H), 7.33 (8H, s, Ar-H), 8.45 (8H, d, Py-H). ¹³C-NMR (125 MHz, CD₂Cl₂, 25 °C): δ(ppm) = 29.5, 31.1, 34.2, 46.2, 52.6, 65.5, 122.8, 127.3, 127.9, 145.7, 149.6, 149.8, 156.7. MS (ESI), m/z: 1313.64 {[M]⁺, calculated 1313.89}. Anal. Calcd. for C₇₆H₉₆N₈O₄S₄•H₂O: C, 68.53%; H, 7.42%; N, 8.41%; Found: C, 68.61%; H, 7.40%; N, 8.40%. UV-vis (CHCl₃/MeOH (1/1)): λ_{max} (nm) / ε (mol⁻¹Lcm⁻¹) = 264(35060). IR (cm⁻¹): ν_{NH}: 3410

Crystallisation conditions

Compound **4**: a vial containing the compound **4** (5 mg, 3.82 10⁻³ mmol) in CHCl₃ (0.5 mL) was placed in a closed beaker containing acetonitrile. Slow vapour diffusion of acetonitrile into the CHCl₃ solution produced, after several days, colourless crystals suitable for X-ray diffraction (Formula: C₇₆H₈₈N₈O₄S₄).

Compound **5**: 2.0 mL of acetonitrile was added to a solution of **5** (5 mg, 4.05 10⁻³ mmol) in CHCl₃ (2.0 mL). Slow evaporation at room temperature produced, after one day, colourless crystals (Formula: C₈₀H₁₀₀N₈O₄•CHCl₃) suitable for X-ray diffraction.

Compound **6**: a vial containing the compound **6** (5 mg, 3.82 10⁻³ mmol) in CHCl₃ (0.5 mL) was placed in a closed beaker containing acetonitrile. Slow vapour diffusion of acetonitrile into the CHCl₃ solution produced, after several days, colourless crystals suitable for X-ray diffraction (Formula: C₇₆H₈₈N₈O₄S₄•CHCl₃).

Compound **8**: a vial containing the compound **8** (5 mg, 3.80 10⁻³ mmol) in CHCl₃ (0.5 mL) was placed in a closed beaker containing acetonitrile. Slow vapour diffusion of acetonitrile into the CHCl₃ solution produced, after several days, colorless crystals suitable for X-ray diffraction (Formula: C₇₆H₉₆N₈O₄S₄).

Acknowledgements

We thank the University of Strasbourg, the C.N.R.S, the International centre for Frontier Research in Chemistry (icFRC), the Labex CSC (ANR-10-LABX- 0026 CSC) within the Investissement d'Avenir program ANR-10-IDEX-0002-02, the Institut Universitaire de France, the Ministère de l'Enseignement Supérieur et de la Recherche for financial support and the Tunisian government for a PhD fellowship to M. H. N.

Notes and references

- (a) C.D. Gutsche in *Calixarenes Revised: Monographs in Supramolecular Chemistry* 6, 1998, *The Royal Society of Chemistry, Cambridge*; (b) Z. Asfari, V. Böhmer, J. Harrowfield and J. Vicens in *Calixarenes*, 2001, (Eds. Z. Asfari, V. Böhmer, J. Harrowfield and J. Vicens) Kluwer Academic, Dordrecht.
- (a) H. Kumagai, M. Hasegawa, S. Miyanari, Y. Sugawa, Y. Sato, T. Hori, S. Ueda, H. Kamiyama and S. Miyano, *Tetrahedron Lett.* 1997, **38**, 3971; (b) H. Akdas, L. Bringel, E. Graf, M. W. Hosseini, G. Mislin, J. Pansanel, A. De Cian and J. Fischer, *Tetrahedron Lett.*, 1998, **39**, 2311; (c) M.W. Hosseini in *Calixarenes* (Eds. Z. Asfari, V. Böhmer, J. Harrowfield, J. Vicens) Kluwer Academic, Dordrecht, 2001, 110.
- G. Mislin, E. Graf, M. W. Hosseini, A. De Cian and J. Fischer, *Tetrahedron Lett.*, 1999, **40**, 1129.
- G. Mislin, E. Graf, M. W. Hosseini and A. De Cian *J. Chem. Soc., Chem. Commun.*, 1998, 1345.
- (a) T. Kajiwar, N. Iki and M. Yamashita *Coord. Chem. Rev.*, 2007, **251**, 1734; (b) B. S. Creavena, D. F. Donlona and J. McGinley *Coord. Chem. Rev.*, 2009, 253, 893
- (a) Y. Kondo, K. Endo and F. Hamada *Chem. Commun.*, 2005, 711; (b) S. P. Bew, A. D. Burrows, T. Düren, M. F. Mahon, P. Z. Moghadam, V. M. Sebestyen and S. Thurston *Chem. Commun.*, **2012**, 4824; (c) Z. Zhang, A. Drapailo, Y. Matvieiev, L. Wojtas and M. J. Zaworotko *Chem. Commun.*, **2013**, 8353.
- (a) G. Mislin, E. Graf, M. W. Hosseini, A. De Cian, N. Kyritsakas and J. Fischer *Chem. Commun.*, 1998, 2545 ; (b) M. N. Kozlova, S. Ferlay, S. E. Solovieva, I. S. Antipin, A. I. Konovalov, N. Kyritsakas and M. W. Hosseini , *Dalton Trans.*, 2007, 5126; (c) M. N. Kozlova, S. Ferlay, S. E. Solovieva, I. S. Antipin, A. I. Konovalov, N. Kyritsakas and M. W. Hosseini *Chem. Commun.*, 2009, 2514. (d) A. Ovsyannikov, S. Ferlay, S. E. Solovieva, I. S. Antipin, A. I. Konovalov, N. Kyritsakas and M. W. Hosseini *Russian Chemical Bulletin*, 2015, **64**, 1955.
- A. S. Ovsyannikov, M. H. Noamane, R. Abidi, S. Ferlay, S. E. Solovieva, I. S. Antipin, A. I. Konovalov, N. Kyritsakas and M. W. Hosseini *CrystEngComm*, 2016, **18**, 691.
- I. I. Stoikov , A. Y. Zhukov, M. N. Agafonova, R. R. Sitdikov, I. S. Antipin and A. I. Konovalov *Tetrahedron*, 2010 **66**, 359.
- A. Kumar, P. Sharma, B. L. Kalal and L. K. Chandel *J. Incl. Phenom. Macrocycl. Chem.*, 2010, **68**, 369.
- (a) A. Ovsyannikov, M. N. Lang, S. Ferlay, S. E. Solovieva, I. S. Antipin, A. I. Konovalov, N. Kyritsakas and M. W. Hosseini *Dalton Trans.*, 2013, 116; (b) A. Ovsyannikov, S. Ferlay, S. E. Solovieva, I. S. Antipin, A. I. Konovalov, N. Kyritsakas and M. W. Hosseini *CrystEngComm*, 2014, 3765; (c) A. Ovsyannikov, S. Ferlay, S. E. Solovieva, I. S. Antipin, A. I. Konovalov, N. Kyritsakas and M. W. Hosseini *Dalton Trans.*, 2013, 9946; (d) A. Ovsyannikov, S. Ferlay, S. E. Solovieva, I. S. Antipin, A. I. Konovalov, N. Kyritsakas and M. W. Hosseini *Inorg. Chem.* 2013, **52**, 6776; (e) A. Ovsyannikov, S. Ferlay, S. E. Solovieva, I. S. Antipin, A. I. Konovalov, N. Kyritsakas and M. W. Hosseini *Dalton Trans.*, 2014, 43, 158; (f) A. Ovsyannikov, S. Ferlay, S. E. Solovieva, I. S. Antipin, A. I. Konovalov, N. Kyritsakas and M. W. Hosseini *Macrocyclics*, 2015, **8**, 113.
- (a) C. Perez-Casas, S. Rahman, N. Begum, Z. Xi and T. Yamato *J. Incl. Phenom. Macrocycl. Chem.*, 2008, **60**, 173 ; (b) X-L. Ni, H. Tomiyasu, T. Shimizu, C. Perez-Casas, Z. Xi and T. Yamato *J. Incl. Phenom. Macrocycl. Chem.*, 2010, **68**, 99.
- a) G. K. Patra and I. Goldberg *Dalton*, 2002, 1051 ; b) G. K. Patra and I. Goldberg *Cryst. Gr. & Des.*, 2003, **3**, 321.
- M. H. Noamane, S. Ferlay, R. Abidi, N. Kyritsakas and M. W. Hosseini, *Dalton*, submitted, 2017.
- (a) C. Danila, M. Bolte and V Böhmer *Org. Biomol. Chem.*, 2005, **3**, 172; (b) S. Barbosa, A. Garcia Carrera, S. E. Matthews, F. Arnaud-Neu, V. Böhmer, J- F. Dozol, H. Rouquette and M-J. Schwing-Weill *J. Chem. Soc., Perkin Trans. 2*, 1999, 719; (c) N. I. Nikishkin, J. Huskens, S. A. Ansari, P. K. Mohapatra and W. Verboom *New J. Chem.*, 2013, **37**, 391.
- (a) I. I. Stoikov, A. V. Galukhin, E. N. Zaikov and I. S. Antipin *Mendelev Commun.*, 2009, **19**, 193; (b) A. V. Galukhin, K. V. Shabalin, I. S. Antipin, A. I. Konovalov and I. I. Stoikov *Mendelev Commun.*, 2013, **23**, 41.
- (a) E. Métay, M-C. Duclos, S. Pellet-Rostaing, M. Lemaire, J. Schulz, R. Kannappan, C. Bucher, E. Saint-Aman and C. Chaix, *Supramol. Chem.*, 2009, **21**, 68; (b) S. Erdemir, P. Deveci, B. Taner and O. Kocyigit *Tetrahedron*, 2012, **68**, 642.
- A. L. Spek, *J. Appl. Crystallogr.*, 2003, **36**, 7.
- G. M. Sheldrick, *Program for Crystal Structure Solution*; University of Göttingen: Göttingen, Germany, **1997**.

Table 3: Crystallographic Parameters for **4**, **5**, **6** and **8** recorded at 173 K.

Formula	4 $C_{76}H_{88}N_8O_4S_4$	5 $C_{80}H_{96}N_8O_4 \cdot CHCl_3$	6 $C_{76}H_{88}N_8O_4S_4 \cdot CHCl_3$	8 $C_{76}H_{96}N_8O_4S_4$
Molecular weight	1305.78	1357.05	1425.15	1313.85
Crystal system	Monoclinic	Monoclinic	Monoclinic	Monoclinic
Space group	$P2_1/n$	$P2_1/n$	$P2_1/n$	$P2_1/n$
a(Å)	14.021(3)	20.9892(10)	20.9999(10)	15.0334(16)
b(Å)	15.136(3)	14.9268(12)	15.0842(6)	13.939(2)
c(Å)	34.374(8)	24.0802(18)	24.1747(13)	36.796(6)
α (deg)	90	90	90	90
β (deg)	93.023(3)	98.511(2)	98.065(2)	107.1990(10)
γ (deg)	90	90	90	90
V(Å ³)	7285(3)	7461.3(9)	7582.0(6)	7641.3(18)
Z	4	4	4	4
Colour	colourless	colourless	colourless	colourless
Crystal dim (mm ³)	0.07 x 0.07 x 0.06	0.07 x 0.07 x 0.06	0.07 x 0.07 x 0.06	0.06 x 0.05 x 0.05
Dcalc (gcm ⁻³)	1.191	1.204	1.248	1.142
F(000)	2784	2888	3016	2816
μ (mm ⁻¹)	0.184	0.178	0.284	0.175
Wavelength (Å)	0.71073	0.71073	0.71073	0.71073
Number of data meas.	56024	41422	51207	20663
Number of data with $I > 2\sigma(I)$	17081 [R(int) = 0.0821]	17812 [R(int) = 0.0539]	22032 [R(int) = 0.0730]	20663 [R(int) = 0.0850]
R	R1 = 0.1090, wR2 = 0.2164	R1 = 0.0861, wR2 = 0.2098	R1 = 0.0883, wR2 = 0.2363	R1 = 0.1068, wR2 = 0.2769
Rw	R1 = 0.1536, wR2 = 0.2415	R1 = 0.1552, wR2 = 0.2474	R1 = 0.2124, wR2 = 0.3068	R1 = 0.2218, wR2 = 0.3205
GOF	1.014	1.027	1.025	1.092
Largest peak in final difference (eÅ ⁻³)	1.562 and -1.132	1.129 and -0.613	0.975 and -0.845	0.991 and -0.725